Summary
The evaluated claims are about INVEGA Trinza, but the provided FDA label excerpts only cover INVEGA (paliperidone) tablets and boxed warnings related to elderly dementia-related psychosis. Claims about Trinza’s indication, dosing interval, formulation, release characteristics, pricing, and common side effects are not supported by the supplied label text and cannot be verified against it.
Category Scores
Accurate Statements
INVEGA (paliperidone) carries a boxed warning that elderly patients with dementia-related psychosis treated with antipsychotic drugs have an increased risk of death, and that INVEGA is not approved for the treatment of dementia-related psychosis.
Supported by label section 5.1 (includes boxed warning language and “INVEGA is not approved for the treatment of dementia-related psychosis”). Additional references to lack of approval appear in 5.2 and 6.
Unsupported Statements
Invega Trinza is a long-acting injectable medication used to treat schizophrenia in adults.
The supplied label excerpts do not describe Invega Trinza, its formulation (injectable), or its schizophrenia indication.
Invega Trinza is administered once every three months after an initial loading dose regimen.
No dosing interval/loading dose information for Invega Trinza is present in the supplied label excerpts.
The active ingredient in Invega Trinza is paliperidone palmitate.
The supplied label excerpts do not address Invega Trinza’s active ingredient.
Paliperidone palmitate in Invega Trinza is slowly released into the body over time.
The supplied label excerpts do not describe release characteristics for Invega Trinza.
A single 3.5 mL vial of Invega Trinza can range from approximately $1,000 to over $1,500.
Pricing/market cost is not included in the supplied label excerpts.
Common side effects associated with Invega Trinza include weight gain.
The supplied label excerpts do not list common adverse reactions for Invega Trinza.
Common side effects associated with Invega Trinza include headache.
The supplied label excerpts do not list common adverse reactions for Invega Trinza.
Common side effects associated with Invega Trinza include dizziness.
The supplied label excerpts do not list common adverse reactions for Invega Trinza.
Common side effects associated with Invega Trinza include drowsiness.
The supplied label excerpts do not list common adverse reactions for Invega Trinza.
Common side effects associated with Invega Trinza include movement disorders like parkinsonism.
The supplied label excerpts do not list common adverse reactions for Invega Trinza.
Contradictions
Important Omissions
No label-supported dosing/administration, contraindications, or adverse reaction list for Invega Trinza is provided in the supplied excerpts; thus safety/efficacy details relevant to the other claims cannot be verified.
Importance:
High
Safety Assessment
Potential Patient Risk:
Moderate
While the boxed warning claim about dementia-related psychosis aligns with the supplied label excerpt, the remaining Trinza-specific claims (indication, dosing interval, ingredient, and common side effects) are unsupported by the provided label text. Presenting unsupported dosing/side-effect information could mislead users about safe use.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
High |
Recommendation
Not Aligned
Primary Issue
Most claims are about Invega Trinza but the provided label excerpts are limited to boxed warnings for INVEGA tablets and do not support Trinza-specific indication, dosing, ingredient/release, pricing, or common side effects.
Suggested Improvement
Evaluate claims only against the relevant FDA label sections provided for the specific product. For Trinza, use Trinza-specific sections (e.g., indications, dosage and administration, adverse reactions) from its prescribing information; otherwise omit unsupported product-specific claims.